Sfoglia per Autore
Incidental finding of anti-mitochondrial antibody: A neglected entity needing reappraisal
2023-01-01 Porcelli, B.; Bizzaro, N.; Fabris, M.; Trevisan, M. T.; Sciarrone, S. S.; Brillanti, S.
Prospective study on the prevalence of HCV infection in consecutive adult inpatients in a hospital division of Internal Medicine in Tuscany
2023-01-01 Pacini, S.; Capecchi, P. L.; Brillanti, S.
Incidental findings of anti-mitochondrial antibodies without evidence of Primary Biliary Cholangitis.
2022-01-01 Mauro, S.; Porcelli, B.; Pilli, T.; Sacco, P.; Bellisai, F.; Frediani, B.; Volterrani, Luca; Castagna, Mg.; Brillanti, S.
Management of Delta Hepatitis 45 years after the discovery of HDV
2022-01-01 Brillanti, S.
Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues—A Delphi Consensus Project
2022-01-01 Borghi, C.; Ciancio, A.; Gentile, I.; Perrone Filardi, P.; Pasqualetti, P.; Brillanti, S.
Primary Biliary cholangitis case-finding: an italian multicenter observational study on patients with incidental finding of anti-mithocondrial antibodies
2022-01-01 Bizzaro, N.; Fabris, M.; Porcelli, B.; Trevisan, Mt.; Sciarrone, Ss.; Palella, E.; Moser, L.; Alessio, Mg.; Romito, A.; Fracchia, M.; Sidoli, L.; Pesce, G.; Labanca, S.; Costantini, A.; Brillanti, S.
The role of gut microbiota in chronic liver diseases
2021-01-01 Brillanti, S.; Alterini, G.
A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy
2021-01-01 Frazzoni, Leonardo; Sikandar, Usama; Mazzella, Giuseppe; Fuccio, Lorenzo; Bazzoli, Franco; Brillanti, Stefano; Azzaroli, Francesco
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis
2021-01-01 Sapena, V.; Enea, M.; Torres, F.; Celsa, C.; Rios, J.; Rizzo, G. E. M.; Nahon, P.; Marino, Z.; Tateishi, R.; Minami, T.; Sangiovanni, A.; Forns, X.; Toyoda, H.; Brillanti, S.; Conti, F.; Degasperi, E.; Yu, M. -L.; Tsai, P. -C.; Jean, K.; El Kassas, M.; Shousha, H. I.; Omar, A.; Zavaglia, C.; Nagata, H.; Nakagawa, M.; Asahina, Y.; Singal, A. G.; Murphy, C.; Kohla, M.; Masetti, C.; Dufour, J. -F.; Merchante, N.; Cavalletto, L.; Chemello, L. L. C.; Pol, S.; Crespo, J.; Calleja, J. L.; Villani, R.; Serviddio, G.; Zanetto, A.; Shalaby, S.; Russo, F. P.; Bielen, R.; Trevisani, F.; Camma, C.; Bruix, J.; Cabibbo, G.; Reig, M.
Screening and detecting significant liver fibrosis in patients with NAFLD: A practical approach using non-invasive tests
2021-01-01 Alterini, G.; Sacco, P.; Formichi, C.; Ciuoli, C.; Ceccarelli, E.; Gonnelli, S.; Volterrani, L.; Castagna, M. G.; Dotta, F.; Brillanti, S.
Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?”
2021-01-01 Capecchi, P. L.; Lazzerini, P. E.; Brillanti, S.
Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation after Direct-Acting Antivirals in HCV Cirrhotic Patients
2020-01-01 Dajti, E.; Ravaioli, F.; Colecchia, A.; Marasco, G.; Bacchi Reggiani, M. L.; Colli, A.; Alemanni, L. V.; Tame, M.; Andreone, P.; Brillanti, S.; Azzaroli, F.; Mazzella, G.; Festi, D.
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals
2019-01-01 Casadei Gardini, A; Foschi, Fg; Conti, F; Petracci, E; Vukotic, R; Marisi, G; Buonfiglioli, F; Vitale, G; Ravaioli, F; Gitto, S; Verucchi, G; Lenzi, M; Bolondi, L; Mazzella, G; Brillanti, S; Andreone, P
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals
2018-01-01 Casadei Gardini, Andrea; Conti, Fabio; Foschi, Francesco Giuseppe; Brillanti, Stefano; Andreone, Pietro
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients
2018-01-01 Ravaioli, F; Dajti, E; Colecchia, A; Alemanni, V; Marasco, G; Tamé, M; Azzaroli, F; Brillanti, S; Mazzella, G; Festi, D
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals
2018-01-01 Ravaioli, Federico; Conti, Fabio; Brillanti, Stefano; Andreone, Pietro; Mazzella, Giuseppe; Buonfiglioli, Federica; Serio, Ilaria; Verrucchi, Gabriella; Bacchi Reggiani, Maria Letizia; Colli, Agostino; Marasco, Giovanni; Colecchia, Antonio; Festi, Davide
Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients
2018-01-01 Ravaioli, Federico; Colecchia, Antonio; Dajti, Elton; Marasco, Giovanni; Alemanni, Luigina Vanessa; Tamè, Mariarosa; Azzaroli, Francesco; Brillanti, Stefano; Mazzella, Giuseppe; Festi, Davide
Direct antiviral therapy for hepatitis C and hepatocellular carcinoma: facing the conundrum
2018-01-01 Buonfiglioli, Federica; Brillanti, Stefano
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis
2018-01-01 Renzulli, Matteo; Buonfiglioli, Federica; Conti, Fabio; Brocchi, Stefano; Serio, Ilaria; Foschi, Francesco Giuseppe; Caraceni, Paolo; Mazzella, Giuseppe; Verucchi, Gabriella; Golfieri, Rita; Andreone, Pietro; Brillanti, Stefano
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients
2017-01-01 Ravaioli, F.; Mazzella, G.; Andreone, P.; Conti, F.; Brillanti, S.; Buonfiglioli, F.; Serio, I.; Verucchi, G.; Bacchi Reggiani, M. L.; Marasco, G.; Colecchia, A.; Festi, D.
| Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
|---|---|---|---|---|
| Incidental finding of anti-mitochondrial antibody: A neglected entity needing reappraisal | 1-gen-2023 | Porcelli, B.; Bizzaro, N.; Fabris, M.; Trevisan, M. T.; Sciarrone, S. S.; Brillanti, S. | - | |
| Prospective study on the prevalence of HCV infection in consecutive adult inpatients in a hospital division of Internal Medicine in Tuscany | 1-gen-2023 | Pacini, S.; Capecchi, P. L.; Brillanti, S. | - | |
| Incidental findings of anti-mitochondrial antibodies without evidence of Primary Biliary Cholangitis. | 1-gen-2022 | Mauro, S.; Porcelli, B.; Pilli, T.; Sacco, P.; Bellisai, F.; Frediani, B.; Volterrani, Luca; Castagna, Mg.; Brillanti, S. | - | |
| Management of Delta Hepatitis 45 years after the discovery of HDV | 1-gen-2022 | Brillanti, S. | - | |
| Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues—A Delphi Consensus Project | 1-gen-2022 | Borghi, C.; Ciancio, A.; Gentile, I.; Perrone Filardi, P.; Pasqualetti, P.; Brillanti, S. | - | |
| Primary Biliary cholangitis case-finding: an italian multicenter observational study on patients with incidental finding of anti-mithocondrial antibodies | 1-gen-2022 | Bizzaro, N.; Fabris, M.; Porcelli, B.; Trevisan, Mt.; Sciarrone, Ss.; Palella, E.; Moser, L.; Alessio, Mg.; Romito, A.; Fracchia, M.; Sidoli, L.; Pesce, G.; Labanca, S.; Costantini, A.; Brillanti, S. | - | |
| The role of gut microbiota in chronic liver diseases | 1-gen-2021 | Brillanti, S.; Alterini, G. | - | |
| A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy | 1-gen-2021 | Frazzoni, Leonardo; Sikandar, Usama; Mazzella, Giuseppe; Fuccio, Lorenzo; Bazzoli, Franco; Brillanti, Stefano; Azzaroli, Francesco | - | |
| Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis | 1-gen-2021 | Sapena, V.; Enea, M.; Torres, F.; Celsa, C.; Rios, J.; Rizzo, G. E. M.; Nahon, P.; Marino, Z.; Tateishi, R.; Minami, T.; Sangiovanni, A.; Forns, X.; Toyoda, H.; Brillanti, S.; Conti, F.; Degasperi, E.; Yu, M. -L.; Tsai, P. -C.; Jean, K.; El Kassas, M.; Shousha, H. I.; Omar, A.; Zavaglia, C.; Nagata, H.; Nakagawa, M.; Asahina, Y.; Singal, A. G.; Murphy, C.; Kohla, M.; Masetti, C.; Dufour, J. -F.; Merchante, N.; Cavalletto, L.; Chemello, L. L. C.; Pol, S.; Crespo, J.; Calleja, J. L.; Villani, R.; Serviddio, G.; Zanetto, A.; Shalaby, S.; Russo, F. P.; Bielen, R.; Trevisani, F.; Camma, C.; Bruix, J.; Cabibbo, G.; Reig, M. | - | |
| Screening and detecting significant liver fibrosis in patients with NAFLD: A practical approach using non-invasive tests | 1-gen-2021 | Alterini, G.; Sacco, P.; Formichi, C.; Ciuoli, C.; Ceccarelli, E.; Gonnelli, S.; Volterrani, L.; Castagna, M. G.; Dotta, F.; Brillanti, S. | - | |
| Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?” | 1-gen-2021 | Capecchi, P. L.; Lazzerini, P. E.; Brillanti, S. | - | |
| Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation after Direct-Acting Antivirals in HCV Cirrhotic Patients | 1-gen-2020 | Dajti, E.; Ravaioli, F.; Colecchia, A.; Marasco, G.; Bacchi Reggiani, M. L.; Colli, A.; Alemanni, L. V.; Tame, M.; Andreone, P.; Brillanti, S.; Azzaroli, F.; Mazzella, G.; Festi, D. | - | |
| Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals | 1-gen-2019 | Casadei Gardini, A; Foschi, Fg; Conti, F; Petracci, E; Vukotic, R; Marisi, G; Buonfiglioli, F; Vitale, G; Ravaioli, F; Gitto, S; Verucchi, G; Lenzi, M; Bolondi, L; Mazzella, G; Brillanti, S; Andreone, P | - | |
| Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals | 1-gen-2018 | Casadei Gardini, Andrea; Conti, Fabio; Foschi, Francesco Giuseppe; Brillanti, Stefano; Andreone, Pietro | - | |
| Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients | 1-gen-2018 | Ravaioli, F; Dajti, E; Colecchia, A; Alemanni, V; Marasco, G; Tamé, M; Azzaroli, F; Brillanti, S; Mazzella, G; Festi, D | - | |
| Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals | 1-gen-2018 | Ravaioli, Federico; Conti, Fabio; Brillanti, Stefano; Andreone, Pietro; Mazzella, Giuseppe; Buonfiglioli, Federica; Serio, Ilaria; Verrucchi, Gabriella; Bacchi Reggiani, Maria Letizia; Colli, Agostino; Marasco, Giovanni; Colecchia, Antonio; Festi, Davide | - | |
| Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients | 1-gen-2018 | Ravaioli, Federico; Colecchia, Antonio; Dajti, Elton; Marasco, Giovanni; Alemanni, Luigina Vanessa; Tamè, Mariarosa; Azzaroli, Francesco; Brillanti, Stefano; Mazzella, Giuseppe; Festi, Davide | - | |
| Direct antiviral therapy for hepatitis C and hepatocellular carcinoma: facing the conundrum | 1-gen-2018 | Buonfiglioli, Federica; Brillanti, Stefano | - | |
| Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis | 1-gen-2018 | Renzulli, Matteo; Buonfiglioli, Federica; Conti, Fabio; Brocchi, Stefano; Serio, Ilaria; Foschi, Francesco Giuseppe; Caraceni, Paolo; Mazzella, Giuseppe; Verucchi, Gabriella; Golfieri, Rita; Andreone, Pietro; Brillanti, Stefano | - | |
| Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients | 1-gen-2017 | Ravaioli, F.; Mazzella, G.; Andreone, P.; Conti, F.; Brillanti, S.; Buonfiglioli, F.; Serio, I.; Verucchi, G.; Bacchi Reggiani, M. L.; Marasco, G.; Colecchia, A.; Festi, D. | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile